QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer

NCT06404463 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

76

Enrollment

OTHER

Sponsor class

Conditions

Early Breast Cancer
Neoadjuvant Therapy
HR+HER2- Breast Cancer

Interventions

DRUG: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
DRUG: Albumin-bound paclitaxel
DRUG: Doxorubicin
DRUG: Cyclophosphamide
DRUG: Epirubicin

Sponsor

Fudan University